It seems like the U.S.-EU trade agreement has left many pharmaceutical firms in the dark regarding tariffs. President Donald Trump announced a “straight across” tariff on “automobiles and everything else,” during a news briefing, while simultaneously suggesting that pharma was “unrelated to this deal.”
“We have 15% for pharmaceuticals. Whatever the decision later on is, of the president of the U.S., how to deal with pharmaceuticals in general globally, that’s on a different sheet of paper,” European Commission President Ursula von der Leyen said Sunday.
The U.S.–EU trade agreement introduces a 15% tariff on most EU imports, including many pharmaceutical products, replacing the previously threatened 30% rate with branded pharmaceuticals largely affected. Although no tariffs are legally enforced yet due to an ongoing U.S. national security review, the industry is bracing for cost increases.
READ: US-India trade deal to be struggling under looming tariffs deadline (July 4, 2025)
EU countries like Ireland, Germany, and Belgium, major exporters of pharmaceutical products, are expected to face up to $19 billion in additional costs. Until the Section 232 investigation concludes, pharmaceutical imports remain tariff-free under WTO terms.
The uncertainty surrounding drug tariffs has triggered warnings from European pharmaceutical companies and industry groups. Many firms are considering shifting production and R&D investments to the U.S., citing concerns over rising export costs and an uncompetitive European regulatory environment. Lobby groups estimate the EU could lose over €100 billion in pharma investment over the next five years if reforms aren’t made.
For the U.S., potential drug price increases and supply chain disruptions could impact healthcare affordability and access. The situation has sparked political backlash in Europe, with some leaders criticizing the agreement as one-sided and detrimental to EU strategic industries.
“The questions around pharma tariffs are highly material, given the volume of imports from the EU,” Wolfe Research analysts wrote in a note Monday.
Medicines and pharmaceutical products represent the EU’s largest export to the U.S., totaling around $120 billion in 2024. Analysts estimate that 15% levies could ramp up industry costs by $13 billion to $19 billion per year, according to Reuters.
“Any surprise increases to the 15% ceiling on pharma tariffs would threaten the broader trade truce,” Eurasia Group analysts wrote in a Monday note.
READ: US ‘very close’ to finalize trade deal with India (July 18, 2025)
“If any dispute about these sectoral tariffs does not sabotage the broader agreement,” the hit to the European economy could be severe, Rabobank analysts added.
The EU and U.S. together represent the largest pharmaceutical market globally, and their cooperation drives research investments, clinical trials, regulatory harmonization, and access to cutting-edge therapies. Any trade barriers risk fragmenting this system, slowing innovation and reducing the speed at which new medicines reach patients.
Furthermore, global challenges like pandemics, antibiotic resistance, and rare diseases require coordinated responses that rely on seamless collaboration between regulators, manufacturers, and researchers. The current tariff uncertainty risks undermining this cooperation at a critical moment for global public health. To safeguard innovation and patient access, policymakers must prioritize transparent negotiations, regulatory alignment, and fair trade practices that support a resilient, innovative pharmaceutical sector.